Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Are employers liable if their employees get COVID-19 at work?
    • Opinion

    Are employers liable if their employees get COVID-19 at work?

    As the government has tightened restrictions on mass gatherings from 500 to 100 people and emphasised the importance of social distancing, many people have been left feeling confused and anxious with exemptions including public transport, schools, and workplaces, just to name a few. Yet an increasing number of institutions seem to be taking it upon

    Read More
    Public
  • After 3 years of development, Janison launches higher education assessment platform
    • News

    After 3 years of development, Janison launches higher education assessment platform

    University students in Singapore will soon be completing exam assessments online with Australian tech company Janison Education (ASX: JAN) having commissioned its online testing platform for the Institute of Technical Education (ITE).  The project was initially conceived in August 2016 when Janison partnered with S&I Systems and were awarded the contract by the Singapore ITE

    Read More
    Public
  • Collateral damage of COVID-19, the deadliest 1% death rate disease
    • Opinion

    Collateral damage of COVID-19, the deadliest 1% death rate disease

    As a sombre storyline attached to the global outbreak of COVID-19, it has become inevitable that the services industry has been decimated, most evidenced by Qantas’ decision to stand down 20,000 of its workforce, and others will follow.  The Qantas decision comes after yesterday’s national address from Prime Minister Scott Morrison who forewarned Australia that

    Read More
    Public
  • FDA grants Oncosil ‘Breakthrough Device’ status in fight against pancreatic cancer
    • News

    FDA grants Oncosil ‘Breakthrough Device’ status in fight against pancreatic cancer

    Accelerating the fight against pancreatic cancer, the United States Food and Drug Administration (FDA) is set to expedite an FDA application from medtech company OncoSil Medical (ASX: OSL) for their pancreatic treatment device.  The OncoSil(™) device has been granted Breakthrough Device Program (BDP) designation which is only granted to medical devices that may provide effective

    Read More
    Public
  • One stock defying the market selldown
    • Opinion

    One stock defying the market selldown

    With news that the COVID-19 virus has shut down more than 20,000 events worldwide, locked many people indoors, and caused a sell down in most commodity markets – it’s a near certainty that we will see recessionary economic growth levels for Q1 and Q2 2020. This is causing share prices to fall at a rate

    Read More
    Public
  • Tinybeans signs 10 partners in two weeks, including Amazon and Apple
    • News

    Tinybeans signs 10 partners in two weeks, including Amazon and Apple

    Despite the significant overall market downturn over the past fortnight, parenting tech company Tinybeans Group (ASX: TNY) has secured a handsome bundle of brand partners keen to use Tinybeans’ platforms to penetrate the lucrative parent and children markets.  The brand partners include Tier 1 partners Amazon, Apple, Kraft and National Geographic Kids as well as

    Read More
    Public
  • «
  • ‹
  • 622
  • 623
  • 624
  • 625
  • 626
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.